Literature DB >> 10700683

Influence of timing and dose of thyroid hormone replacement on development in infants with congenital hypothyroidism.

J J Bongers-Schokking1, H M Koot, D Wiersma, P H Verkerk, S M de Muinck Keizer-Schrama.   

Abstract

OBJECTIVES: To test whether early treatment with a high initial dose of levothyroxine can prevent suboptimal mental development in all neonates with congenital hypothyroidism (CH). STUDY
DESIGN: Sixty-one patients, 27 with severe CH and 34 with mild CH, were treated either early (<13 days) or late (> or =13 days) with either a high initial dose of levothyroxine (> or =9.5 microg/kg/d) or a low initial dose (<9.5 microg/kg/d). With these criteria, 4 treatment groups were formed. The results of the Bayley test, performed at the age of 10 to 30 months and expressed as mental developmental index (MDI) and psychomotor developmental index (PDI), were related to socioeconomic status, treatment group, initial free thyroxine (FT(4)) concentration, and mean FT(4) concentration during the first 3 months of treatment (FT(4)-A) and the ensuing 9 months (FT(4)-B).
RESULTS: Mean (+/- SD) MDI was 113 +/- 14, and mean PDI was 114 +/- 12. In the severe CH group, only the patients treated early with a high initial dose had normal MDI scores (124 +/- 16), whereas the scores of the other groups ranged from 97 to 103. In contrast, all patients in the mild CH group had normal scores (range, 122-125), except those in the group treated late with a low initial dose, whose score was 110 +/- 10. Forty-three percent of the variance in MDI and PDI scores was explained by treatment factors, such as the treatment group, initial FT(4) concentration, FT(4)-A, and FT(4)-B.
CONCLUSIONS: Our data suggest that optimal treatment includes achievement of euthyroidism before the third week of life by initiation of therapy before 13 days with a levothyroxine dose above 9.5 microg/kg/d and maintenance of FT(4) concentrations in the upper normal range during the first year. Thus treated, patients with CH can achieve normal psychomotor development at 10 to 30 months, irrespective of the severity of the disease.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10700683     DOI: 10.1067/mpd.2000.103351

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  32 in total

1.  Optimisation of thyroxine dose in congenital hypothyroidism.

Authors:  P C Hindmarsh
Journal:  Arch Dis Child       Date:  2002-02       Impact factor: 3.791

2.  Prevalence of maternal dietary iodine insufficiency in the north east of England: implications for the fetus.

Authors:  M S Kibirige; S Hutchison; C J Owen; H T Delves
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2004-09       Impact factor: 5.747

3.  Cretinism: The past, present and future of diagnosis and cure.

Authors:  Sonia Salisbury
Journal:  Paediatr Child Health       Date:  2003-02       Impact factor: 2.253

Review 4.  Thyroid hormone and cerebellar development.

Authors:  Grant W Anderson
Journal:  Cerebellum       Date:  2008       Impact factor: 3.847

5.  Individualized treatment to optimize eventual cognitive outcome in congenital hypothyroidism.

Authors:  Jacoba J Bongers-Schokking; Wilma C M Resing; Wilma Oostdijk; Yolanda B de Rijke; Sabine M P F de Muinck Keizer-Schrama
Journal:  Pediatr Res       Date:  2016-08-05       Impact factor: 3.756

Review 6.  Overview of diagnosis, management and outcome of congenital hypothyroidism: A call for a national screening programme in Sudan.

Authors:  Amir M I Babiker; Nasir A Al Jurayyan; Sarar H Mohamed; Mohamed A Abdullah
Journal:  Sudan J Paediatr       Date:  2012

7.  Clinical practice: experience with newborn screening for congenital hypothyroidism in the Republic of Macedonia - a multiethnic country.

Authors:  Mirjana Kocova; Violeta Anastasovska; Elena Sukarova-Angelovska; Milica Tanaskoska; Elizabeta Taseva
Journal:  Eur J Pediatr       Date:  2014-09-07       Impact factor: 3.183

Review 8.  Early diagnosis of neonatal cholestatic jaundice: test at 2 weeks.

Authors:  Eric I Benchimol; Catharine M Walsh; Simon C Ling
Journal:  Can Fam Physician       Date:  2009-12       Impact factor: 3.275

Review 9.  Congenital hypothyroidism.

Authors:  Maynika V Rastogi; Stephen H LaFranchi
Journal:  Orphanet J Rare Dis       Date:  2010-06-10       Impact factor: 4.123

Review 10.  Thyroid-disrupting chemicals: interpreting upstream biomarkers of adverse outcomes.

Authors:  Mark D Miller; Kevin M Crofton; Deborah C Rice; R Thomas Zoeller
Journal:  Environ Health Perspect       Date:  2009-02-12       Impact factor: 9.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.